Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe

Global Cord Blood (CO US): No Immediate Respite Is Seen

Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation

Quiddity Advisors

Event-Driven

On the 4 June 2019, <a href="https://www.smartkarma.com/entities/cordlife-group-ltd" target="_blank" data-smartkarma-citation="entities:568:1" rel="noopener">Cordlife (CLGL SP)</a> <a href="https://links.sgx.com/FileOpen/CGL%20SGX%20-%20Announcement%20of%20Indicative%20Non-Binding%20Proposal.ashx?App=Announcement&amp;FileID=562493" target="_blank" rel="noopener">announced</a> a non-binding proposal for <a href="https://www.smartkarma.com/entities/global-cord-blood-corp" target="_blank" data-smartkarma-citation="entities:689:1" rel="noopener">Global Cord Blood (CO US)</a> (GCB), via the issuance of 2.497bn shares worth S$1.248bn or an indicative Offer Price of US$7.50/share. The transaction was subject to the entry into a definitive transaction documentation, including a merger agreement following satisfactory completion of business, financial, legal, and other due diligence.
Some 18 months later, Cordlife announced the <a href="https://links.sgx.com/FileOpen/CGL_SGX_Termination_of_discussion_Indicative_Non-Binding_Proposal.ashx?App=Announcement&amp;FileID=648215" target="_blank" rel="noopener">termination</a> of the proposal.
<h3>The NEW News</h3>
On the 2 March, less than a month after Cordlife walked away, GCB <a href="https://ir.globalcordbloodcorp.com/static-files/f8b2aceb-b2fb-4de7-b9ea-5e466584ceda" target="_blank" rel="noopener">announced</a> the receipt of a non-binding acquisition proposal from a wholly-owned subsidiary of <a href="https://www.smartkarma.com/entities/haitong-international-securities-group-ltd" target="_blank" data-smartkarma-citation="entities:13153:1" rel="noopener">Haitong International Securities Group (665 HK)</a>. The consideration under the proposal is US$5/share.
Yesterday GCB <a href="https://ir.globalcordbloodcorp.com/static-files/57848e55-d492-4a0b-8eee-03e431935b68" target="_blank" rel="noopener">announced</a> the formation of a special committee to evaluate the proposal.
More below the fold.

On the 4 June 2019, Cordlife (CLGL SP) announced a non-binding proposal for Global Cord Blood (CO US) (GCB), via the issuance of 2.497bn shares worth S$1.248bn or an indicative Offer Price of US$7.50/share. The transaction was subject to the entry into a definitive transaction documentation, including a merger agreement following satisfactory completion of business, financial, legal, and other due diligence.
Some 18 months later, Cordlife announced the termination of the proposal.
The NEW News
On the 2 March, less than a month after Cordlife walked away, GCB announced the receipt of a non-binding acquisition proposal from a wholly-owned subsidiary of Haitong International Securities Group (665 HK). The consideration under the proposal is US$5/share.
Yesterday GCB announced the formation of a special committee to evaluate the proposal.
More below the fold.

Haitong Securities Co Ltd (A) (600837 CH)

Haitong International Securities Group (665 HK)

Global Cord Blood: Haitong Raids The Bank